Related Experiment Videos

Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials

Brian J Wells1, Arch G Mainous, Lori M Dickerson

  • 1Department of Family Medicine, Medical University of South Carolina, Charleston, SC 29245, USA. wellsbj@musc.edu

Archives of Internal Medicine
|October 27, 2004
PubMed

Insights

Antibiotics targeting Chlamydia pneumoniae infections did not significantly reduce recurrent cardiac events or mortality in patients with established ischemic heart disease (IHD). This meta-analysis found no overall benefit for antibiotic use in secondary IHD prevention.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Epidemiology

Background:

  • Infections, particularly Chlamydia pneumoniae, have been implicated in ischemic heart disease (IHD) pathogenesis for over a century.
  • Antibiotic use for secondary IHD prevention has yielded conflicting results in clinical trials.
  • C. pneumoniae presence in atherosclerotic plaques and elevated antibody titers correlate with myocardial infarction risk.

Purpose of the Study:

  • To conduct a meta-analysis of randomized controlled trials (RCTs) evaluating antibiotic efficacy in the secondary prevention of IHD.
  • To assess the impact of antibiotics effective against C. pneumoniae on clinical outcomes in patients with known IHD.

Main Methods:

  • Meta-analysis of published, well-designed randomized controlled trials (RCTs).
  • Inclusion criteria: antibiotics targeting C. pneumoniae, patients with known IHD, and assessment of IHD-related clinical outcomes.
  • Analysis included 9 studies with 11,015 participants.

Main Results:

  • Four of nine studies reported a benefit from antibiotic treatment; five found no effect.
  • The combined analysis showed no significant reduction in cardiovascular events (RR, 0.94; 95% CI, 0.86-1.03) or mortality (RR, 0.94; 95% CI, 0.79-1.12).
  • Funnel plot analysis did not indicate publication bias.

Conclusions:

  • Macrolide antibiotics targeting C. pneumoniae did not achieve statistically significant reductions in recurrent cardiac events or mortality in patients with known IHD.
  • The study duration ranged from 3 months to 3 years across the included trials.
  • Current evidence does not support the routine use of these antibiotics for secondary prevention of IHD.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...